Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Managing the supportive care needs of those affected by COVID-19

S. Bajwah, A. Wilcock, R. Towers, M. Costantini, C. Bausewein, S. T. Simon, E. Bendstrup, W. Prentice, M. J. Johnson, D. C. Currow, M. Kreuter, A. U. Wells, S. S. Birring, P. Edmonds, I. J. Higginson
European Respiratory Journal 2020; DOI: 10.1183/13993003.00815-2020
S. Bajwah
1Palliative Care, Cicely Saunders Institute, Department of Palliative Care Policy and Rehabilitation, King's College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for S. Bajwah
A. Wilcock
2Medical Oncology and Palliative Medicine, University of Nottingham, Nottingham, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for A. Wilcock
R. Towers
3Matron Palliative Care, Department of Palliative Care, King's College Hospital, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Costantini
4Scientific Director, Azienda USL-IRCCS di Reggio Emilia, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Bausewein
5alliative Medicine, Department of Palliative Medicine, LMU Klinikum, Ludwig-Maximilians-University, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. T. Simon
6Department of Palliative Medicine and Center for Integrated Oncology, University of Cologne, Faculty of Medicine and University Hospital, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
E. Bendstrup
7Centre for Rare Lung Diseases, Department of Respiratory Diseases and Allergy, Aarhus University Hospital, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
W. Prentice
8Palliative Care, Department of Palliative Care, King's College Hospital, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. J. Johnson
9Palliative Care, Wolfson Palliative Care Research Centre, Hull York Medical School, University of Hull, Hull, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. C. Currow
10Palliative Care, IMPACCT, Faculty of Health, University of Technology Sydney, Ultimo, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Kreuter
11Center for interstitial and rare lung diseases, Thoraxklinik, University of Heidelberg, Germany and German Center for Lung Research, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. U. Wells
12Interstitial Lung Disease, Royal Brompton Hospital, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. S. Birring
13Respiratory Medicine, Centre for Human & Applied Physiological Sciences, School of Basic & Medical Biosciences, Faculty of Life Sciences & Medicine, King's College London, London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. Edmonds
8Palliative Care, Department of Palliative Care, King's College Hospital, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
I. J. Higginson
1Palliative Care, Cicely Saunders Institute, Department of Palliative Care Policy and Rehabilitation, King's College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for I. J. Higginson
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Globally, the number of people affected by coronavirus disease 2019 (COVID-19) is rapidly increasing. In most (>80%), the illness is relatively mild and can be self-managed out of hospital. However, in about 20% the illness causes respiratory compromise severe enough to require hospital admission [1]. Patients with severe and critical disease need full active treatment. This may include oxygen for hypoxaemia and ventilatory support, along with optimal management of complications, e.g. super-imposed bacterial infection, and any underlying co-morbidities, e.g. chronic obstructive pulmonary disease, congestive heart failure. To date, no antiviral agent has shown to be effective in treating the disease [2].

Patients with severe disease not considered suitable for escalation to intensive care, i.e. those who are frail or have multiple co-morbidities, are at very high risk of dying, with an estimated death rate of 15–22% [3, 4]. We have a moral obligation to provide good symptom control to prevent avoidable suffering. Thus, comprehensive care of the patient with COVID-19 requires identification of patients at increased risk of dying, who would benefit from a parallel approach to management. This encompasses optimal symptom management for those with severe disease but who will survive, and expert symptom management and end of life care for those that are deteriorating and in their last days–hours of life. The aim of this editorial is to provide a succinct informative overview to guide respiratory healthcare professionals on the frontline.

Symptom relief

The most common symptoms are breathlessness, cough and fever.

Breathlessness (5–65%) [5–9]

The highest incidence will be in those with severe disease and is expected in those actively dying. The primary driver of breathlessness is the viral lung infection causing an interstitial pneumonia with a reduction in lung diffusing capacity; in some patients this evolves to Acute Respiratory Distress Syndrome (ARDS). The experience of breathlessness is also influenced by emotional, environmental, cultural and social factors, and optimal management requires a holistic approach. These include non-pharmacological and pharmacological approaches. Non-pharmacological approaches include breathing techniques [10]. Although an electric hand-held fan directed at the face is helpful in other settings [10, 11], this is not recommended in COVID-19 because of the theoretical infection control risk of spreading infected droplets. As an alternative, use of facial cooling with wet wipes (binning after each use, as for tissues) can be tried.

Pharmacological approaches are the mainstay of management for patients with severe disease who are likely to have rapidly worsening breathlessness at rest. Morphine is the opioid of choice [12, 13]. However, alternative strong opioids can be used. Short-acting oral opioids, given as required, may suffice when breathlessness is mild. However, in severe disease or at the end of life, continuous infusions of parenteral opioids are preferable, maximising symptom management whilst reducing nurse and community staff time, use of resource limited protective equipment and exposure. Use of the parenteral route is also preferred for speed of onset of action and ability to rapidly titrate doses. If there is distressing breathlessness at rest, opioids should be combined with an anxiolytic sedative, e.g. midazolam (table 1). Rapid titration of benzodiazepines may be needed. The primary role of oxygen is to correct hypoxaemia. There is a suggestion it may help breathlessness in severe hypoxaemia [14], but not when mild or absent [15]. In a comatose/unresponsive dying patient, oxygen can be titrated down with goal of discontinuation, while concurrently managing symptoms of breathlessness [16].

View this table:
  • View inline
  • View popup
TABLE 1

Example clinical guidelines for the management of the severe/dying COVID-19 patient

Cough (70–80%) [5–9]

Potential mechanisms in viral respiratory infection and ARDS include inflammation, epithelial damage, mucus impaction and neuro-modulatory changes (heightened cough reflex sensitivity) [17]. Evidence for effective management of acute cough is limited [18, 19]. Adequate hydration and regular small sips of water may help [20]. However, because of the likely concurrent need for breathlessness management, strong opioids are likely to be more pragmatic in practice. High-level evidence is limited [21, 22], but relatively low doses of long-acting oral morphine (5–10 mg twice daily) are helpful in refractory chronic cough (table 1) [21]. Although these patients do not have chronic cough, opioids may be helpful in reducing cough alongside treatment for breathlessness [22].

Delirium

Delirium is common in medical illness and almost universal in the last days–hours of life. Non-pharmacological management includes regular orientation, avoiding constipation, treating pain, maintaining oxygenation and avoiding urinary retention [23]. When ineffective and where the delirium is causing significant distress, pharmacological therapy with an antipsychotic (such as haloperidol) should be considered; in the context of severe breathlessness and at the end of life, a sedative anxiolytic such as levomepromazine or midazolam should be used (See table 1) to allow rapid titration if needed.

Anxiety

Anxiety secondary to breathlessness, social isolation and fear is likely to be present to some degree in all patients with COVID-19. Severely ill patients may be particularly distressed, due to the looming possibility that their situation may rapidly worsen and that they may die, potentially compounded by the loss of support from their families, who are not allowed to visit, and receiving care from health professionals in personal protective equipment. Non-pharmacological methods such as relaxation therapy and breathing exercises are effective in mild anxiety but if patients are significantly anxious or have severe disease, the focus should be on pharmacological management. For severe disease and if people are actively dying, benzodiazepines are likely to be most effective [24]. Optimal relief may necessitate increasing depths of sedation rapidly in the last days–hours or of life, particularly when associated with severe breathlessness (See table 1).

Psychological support

Families of patients with COVID-19 face a significant psychological burden that is often magnified by family members themselves being in isolation or under financial strain. Often, more than one member of the same family may be infected and in hospital. Visiting is likely to also be limited/prohibited. There may also be guilt over possibly transmitting the infection to their loved one. The quality of the dying experience and lack of preparation for the death are both predictors of complicated grief. Health professionals should communicate with families regularly and where possible facilitate communication between patients and their families utilising virtual technology [25]. Information leaflets should be provided for both patients and family members. If family members are unable to visit, leaflets should be emailed where possible. See figures 1 and 2 for example leaflets that can be used and supplementary files for downloadable editable WORD documents.

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

Example information sheet for COVID-19 patients admitted to hospital (downloadable WORD document available in supplementary files).

FIGURE 2
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 2
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 2

Example information sheet for familes/friends of COVID-19 patients admitted to hospital (downloadable WORD document available in supplementary files).

Information needs and parallel planning

In patients with severe disease, there is a need for parallel planning- hoping for the best but preparing for the worst. Therefore, there is an urgent need for early and honest discussions at the time of hospitalisation/diagnosis of COVID-19 for those with a high risk of severe illness and death. Health professionals should focus on advance care planning with open and honest conversations as to what is important to the individual, to inform treatment escalation planning including resuscitation status, should they deteriorate.

Health professionals should acknowledge the distress of this complex and unique situation, and be compassionate, respectful and empathic. We must explain that active resuscitative care and symptom management do not need to be mutually exclusive, where resources allow. The focus of care should be iterative, adapting to worsening clinical status or patient expressed altered goals of care. Importantly, healthcare professionals need to be proactive in the provision of information and ensure that if there is a significant possibility that the patient will die, that this is addressed with both the patient and family (table 1).

Spiritual Care

The importance of spirituality in coping with uncertainty, severe disease and at the end of life is recognised [26]. Spiritual wellbeing offers some protection against end of life despair in those for whom death is imminent [26]. Hospital chaplains provide spiritual care that helps patients facing serious illness better cope with their symptoms and prognosis. Most hospitals around the world will have chaplains/representatives from all faiths in the chaplaincy office. The family of the patient or the dying patient may want to see speak to someone about their impending death. Chaplain interventions, whether or not religious, focused on comforting the patient and improving his or her well-being in the context of both his or her spiritual pain and critical illness should be explored with all patients and carers [27]. It is important that the spiritual care needs of those who are not represented by chaplaincy available or who are not religious, should also be addressed.

Conclusion

COVID-19 patients with severe disease/at the end of life have an equal right to care. Receiving adequate symptom control is a basic human right and we have a fundamental duty to relieve suffering and provide the best care with the available resources regardless of the chances of survival.

Acknowledgments

Thank you to all the patients and members of the public at the European Lung Foundation and Cicely Saunders Institute as well as Howard Almond (Action for Pulmonary Fibrosis) and Sarah Dix for their valuable contributions to drafting of the information leaflets.

Footnotes

  • Support statement: This study/project is supported by the National Institute for Health Research (NIHR) Applied Research Collaboration South London (NIHR ARC South London) at King's College Hospital NHS Foundation Trust. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

  • Conflict of interest: Dr. Bajwah has nothing to disclose.

  • Conflict of interest: Dr. Wilcock has nothing to disclose.

  • Conflict of interest: Dr. Towers has nothing to disclose.

  • Conflict of interest: Dr. Costantini has nothing to disclose.

  • Conflict of interest: Dr. Bausewein has nothing to disclose.

  • Conflict of interest: Dr. Simon has nothing to disclose.

  • Conflict of interest: Dr. Bendstrup has nothing to disclose.

  • Conflict of interest: Dr. Prentice has nothing to disclose.

  • Conflict of interest: Dr. Johnson has nothing to disclose.

  • Conflict of interest: Dr. Currow has nothing to disclose.

  • Conflict of interest: Dr. Kreuter has nothing to disclose.

  • Conflict of interest: Dr. Wells has nothing to disclose.

  • Conflict of interest: Dr. Birring has nothing to disclose.

  • Conflict of interest: Dr. Edmonds has nothing to disclose.

  • Conflict of interest: Dr. Higginson has nothing to disclose.

  • Received March 23, 2020.
  • Accepted April 5, 2020.
  • Copyright ©ERS 2020
http://creativecommons.org/licenses/by-nc/4.0/

This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

References

  1. ↵
    1. WHO-China Joint Mission
    . Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) 2020. www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf [cited 2020 17 March 2020].
  2. ↵
    1. Rubin EJ,
    2. Baden LR,
    3. Morrissey S
    . Audio Interview: New Research on Possible Treatments for Covid-19. N Engl J Med 2020; 382: e30. doi:10.1056/NEJMe2005759
    OpenUrl
  3. ↵
    1. Zhou F,
    2. Yu T,
    3. Du R, et al.
    Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020.
  4. ↵
    1. Guan W-j,
    2. Liang W-h,
    3. Zhao Y, et al.
    Comorbidity and its impact on 1,590 patients with COVID-19 in China: A Nationwide Analysis. medRxiv 2020.
  5. ↵
    1. Guan W-j,
    2. Ni Z-y,
    3. Hu Y, et al.
    Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020.
    1. Yang X,
    2. Yu Y,
    3. Xu J, et al.
    Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020.
    1. Xu X-W,
    2. Wu X-X,
    3. Jiang X-G, et al.
    Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ 2020; 368: m606. doi:10.1136/bmj.m606
    OpenUrlAbstract/FREE Full Text
    1. Wang L,
    2. Gao Y-h,
    3. Zhang G-J
    . The clinical dynamics of 18 cases of COVID-19 outside of Wuhan, China. Eur Respir J 2020.
  6. ↵
    1. Zhang S,
    2. Li H,
    3. Huang S, et al.
    High-resolution CT features of 17 cases of Corona Virus Disease 2019 in Sichuan province, China. Eur Respir J 2020.
  7. ↵
    1. Higginson IJ,
    2. Bausewein C,
    3. Reilly CC, et al.
    An integrated palliative and respiratory care service for patients with advanced disease and refractory breathlessness: a randomised controlled trial. Lancet Respir Med 2014; 2: 979–987. doi:10.1016/S2213-2600(14)70226-7
    OpenUrl
  8. ↵
    1. Gysels M,
    2. Reilly CC,
    3. Jolley CJ, et al.
    How does a new breathlessness support service affect patients? Eur Respir J 2015; 46: 1515–1518. doi:10.1183/13993003.00751-2015
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Ekström M,
    2. Nilsson F,
    3. Abernethy AA, et al.
    Effects of opioids on breathlessness and exercise capacity in chronic obstructive pulmonary disease. A systematic review. Ann Am Thorac Soc 2015; 12: 1079–1092. doi:10.1513/AnnalsATS.201501-034OC
    OpenUrlCrossRefPubMed
  10. ↵
    1. Ekström M,
    2. Bajwah S,
    3. Bland JM, et al.
    One evidence base; three stories: do opioids relieve chronic breathlessness? Thorax 2018; 73: 88–90. doi:10.1136/thoraxjnl-2016-209868
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Bruera E,
    2. de Stoutz N,
    3. Velasco-Leiva A, et al.
    Effects of oxygen on dyspnoea in hypoxaemic terminal-cancer patients. Lancet 1993; 342: 13–14. doi:10.1016/0140-6736(93)91880-U
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    1. Abernethy AP,
    2. McDonald CF,
    3. Frith PA, et al.
    Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial. Lancet 2010; 376: 784–793. doi:10.1016/S0140-6736(10)61115-4
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    1. Campbell ML,
    2. Yarandi H,
    3. Dove-Medows E
    . Oxygen is nonbeneficial for most patients who are near death. J Pain Symptom Manage 2013; 45: 517–523. doi:10.1016/j.jpainsymman.2012.02.012
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    1. Atkinson SK,
    2. Sadofsky LR,
    3. Morice AH
    . How does rhinovirus cause the common cold cough? BMJ Open Respir Res 2016; 3: e000118.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Malesker MA,
    2. Callahan-Lyon P,
    3. Ireland B, et al.
    Pharmacologic and nonpharmacologic treatment for acute cough associated with the common cold: CHEST Expert Panel Report. Chest 2017; 152: 1021–1037. doi:10.1016/j.chest.2017.08.009
    OpenUrl
  16. ↵
    1. Hill AT,
    2. Gold PM,
    3. El Solh AA, et al.
    Adult outpatients with acute cough due to suspected pneumonia or influenza: CHEST Guideline and Expert Panel Report. Chest 2019; 155: 155–167. doi:10.1016/j.chest.2018.09.016
    OpenUrl
  17. ↵
    1. Mitchell SAC,
    2. Garrod R,
    3. Clark L, et al.
    Physiotherapy, and speech and language therapy intervention for patients with refractory chronic cough: a multicentre randomised control trial. Thorax 2017; 72: 129–136. doi:10.1136/thoraxjnl-2016-208843
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Fuller RW,
    2. Karlsson JA,
    3. Choudry NB, et al.
    Effect of inhaled and systemic opiates on responses to inhaled capsaicin in humans. J Appl Physiol 1988; 65: 1125–1130. doi:10.1152/jappl.1988.65.3.1125
    OpenUrlPubMedWeb of Science
  19. ↵
    1. Morice AH,
    2. Millqvist E,
    3. Bieksiene K, et al.
    ERS guidelines on the diagnosis and treatment of chronic cough in adults and children. Eur Respir J 2020; 55. doi:10.1183/13993003.01136-2019
  20. ↵
    1. Network
    . SIG. Risk reduction and Management of delirium, 2019. www.sign.ac.uk/sign-157-delirium [cited March 2020].
  21. ↵
    Practice guideline for the treatment of patients with panic disorder. Work Group on Panic Disorder. American Psychiatric Association. Am J Psychiatry 1998; 155: 5 Suppl., 1–34.
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    1. Lobb EA,
    2. Kristjanson LJ,
    3. Aoun SM, et al.
    Predictors of Complicated Grief: A Systematic Review of Empirical Studies. Death Stud 2010; 34: 673–698. doi:10.1080/07481187.2010.496686
    OpenUrlCrossRefPubMedWeb of Science
  23. ↵
    1. McClain CS,
    2. Rosenfeld B,
    3. Breitbart W
    . Effect of spiritual well-being on end-of-life despair in terminally-ill cancer patients. Lancet 2003; 361: 1603–1607. doi:10.1016/S0140-6736(03)13310-7
    OpenUrlCrossRefPubMedWeb of Science
  24. ↵
    1. Berning JN,
    2. Poor AD,
    3. Buckley SM, et al.
    A novel picture guide to improve spiritual care and reduce anxiety in mechanically ventilated adults in the intensive care unit. Ann Am Thorac Soc 2016; 13: 1333–1342. doi:10.1513/AnnalsATS.201512-831OC
    OpenUrl
PreviousNext
Back to top
View this article with LENS
Vol 61 Issue 2 Table of Contents
European Respiratory Journal: 61 (2)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Managing the supportive care needs of those affected by COVID-19
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Managing the supportive care needs of those affected by COVID-19
S. Bajwah, A. Wilcock, R. Towers, M. Costantini, C. Bausewein, S. T. Simon, E. Bendstrup, W. Prentice, M. J. Johnson, D. C. Currow, M. Kreuter, A. U. Wells, S. S. Birring, P. Edmonds, I. J. Higginson
European Respiratory Journal Jan 2020, 2000815; DOI: 10.1183/13993003.00815-2020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Managing the supportive care needs of those affected by COVID-19
S. Bajwah, A. Wilcock, R. Towers, M. Costantini, C. Bausewein, S. T. Simon, E. Bendstrup, W. Prentice, M. J. Johnson, D. C. Currow, M. Kreuter, A. U. Wells, S. S. Birring, P. Edmonds, I. J. Higginson
European Respiratory Journal Jan 2020, 2000815; DOI: 10.1183/13993003.00815-2020
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Symptom relief
    • Psychological support
    • Information needs and parallel planning
    • Spiritual Care
    • Conclusion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Commemorating World Tuberculosis Day 2022
  • Is low level of vitamin D a marker of poor health or its cause?
  • Risky political game with climate change
Show more Editorial

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society